Our story so far
From day one, Agendia was founded on the belief we could improve the quality of life for cancer patients everywhere. Today, our genomic tests are achieving this goal with a broad and growing global customer base, including many major hospitals and clinical institutions. Through every step, we continue to stay focused on providing the innovation and dedication that helps patients live better lives.
Here are a few of our company highlights:
- 2003 — Agendia was founded as a spin-off of the Netherlands Cancer Institute in Amsterdam
- 2004 — We launched our flagship breast cancer risk of recurrence test, MammaPrint, in Europe
- 2007 — MammaPrint became the first IVDMIA* to gain 510(k) clearance from the FDA,
and has since received six additional FDA clearances
- 2007 — We launched MammaPrint in the US
- 2010 — We introduced our second breast cancer test, BluePrint, a molecular subtyping test
- 2016 — The landmark MINDACT trial was published, demonstrating the clinical utility of MammaPrint with the highest possible level of evidence (level 1A)
- 2017 — MammaPrint was recommended in prestigious clinical practice guidelines including ASCO,
the only test of its kind recommended for both lymph node-negative and lymph node-positive patients
- 2017 — Publication of the STO-3 trial demonstrated that patients with a MammaPrint Late recurrence (20-year) Low Risk result had excellent breast cancer-specific survival, 20 years after diagnosis with little or no hormone therapy
- 2018 — The MammaPrint and BluePrint Kit attained the CE mark, allowing leading cancer centers across Europe to run these tests in their own labs using their existing next-generation sequencing (NGS) technology†
- 2018 — MammaPrint and BluePrint were launched to patients and physicians in China
- 2018 — NCCN guideline inclusion
- 2020 — Long Term Follow Up MINDACT Data Presented
It’s the collective responsibility of every stakeholder in the cancer-care ecosystem to deliver precision oncology so we can minimize cancer patients’ suffering and enable them to live the longest and healthiest lives possible.
Our vision for the future
We have a pipeline of exciting genomic products in development, which include more predictive breast cancer tests based on a growing set of data.
Having recently launched our CE-marked NGS-based MammaPrint BluePrint Kit in Europe, we plan to expand this offering to a wider range of markets so that many more labs can use our test in-house.
As for research, we collaborate with pharmaceutical companies, academic institutions, and some of the world’s leading cancer centers to continue our studies in genomics and genomic testing. Right now, we’re a critical partner in the ongoing I-SPY2 and FLEX Registry clinical trials and PRECiSE study (Netherlands), creating the most comprehensive data sets.
Where to next?
IVDMIA = in vitro diagnostic multivariate index assay†
Next-generation sequencing is a newer form of DNA sequencing technology. In addition to reducing the costs and time to sequence DNA, sequencing can be conducted with smaller samples.